RxDoctor Payments Data

Anita Vaughn, MD

Internal Medicine · Clinton, MDNPI 1578503942

Payments from drug & device makers

$14,209in general payments, 2019–2025

Across 34 payments — averaging $417.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$14K
  • Novo Nordisk$250
  • Merck$141
  • Viiv Healthcare Company$125
  • Johnson & Johnson$25
  • Teva Pharmaceuticals USA, Inc.$20

What the payments were for

  • Speaking & faculty fees$12,24086%
  • Travel & lodging$1,0457%
  • Food & beverage$9247%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead21$13,650
Novo Nordisk2$250
Merck7$141
Viiv Healthcare Company1$125
Johnson & Johnson(2 entities)2$25
Teva Pharmaceuticals USA, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,209 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$21,901
Medicare patients
121
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$38,004
JardianceEmpagliflozin43$26,948
EliquisApixaban25$14,642
EntrestoSacubitril/Valsartan17$10,293
Atrovent HfaIpratropium Bromide11$5,291
Novolog FlexpenInsulin Aspart19$2,362
Albuterol Sulfate HfaAlbuterol Sulfate45$1,518
Lidocaine13$1,501
Wixela InhubFluticasone Propion/Salmeterol14$1,440
Atorvastatin Calcium151$985
Ketoconazole37$759
Fluticasone Propionate46$485
Lisinopril189$454
Tamsulosin Hcl51$434
Levothyroxine Sodium79$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$250$38,00439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →